Medicare Enrolled
Dr. Keith Harris, DO
Pulmonary Disease · Port Jefferson Station, NY
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Harris from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Harris?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Harris
Dr. Keith Harris is a pulmonary disease specialist in Port Jefferson Station, NY, with 19 years of NPI registration. Based on federal Medicare data, Dr. Harris performed 7,086 Medicare services across 5,690 unique beneficiaries.
Between the years covered by Open Payments, Dr. Harris received a total of $673,909 from 45 pharmaceutical and/or device companies across 1347 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Harris is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 4% volume in NY
$673,909 industry payments
Medicare Practice Summary
Medicare Utilization ↗7,086
Medicare services
Top 4% in NY for pulmonary disease
5,690
Unique beneficiaries
$69
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~373 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,867 | $116 | $360 |
| Airflow rate measurement test A test that measures the rate of airflow. This procedure assesses how quickly air moves. |
1,038 | $35 | $141 |
| Lung volume measurement test A test that measures the largest amount of air you can breathe in and out. It evaluates the total capacity of your lungs. |
962 | $14 | $110 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
957 | $53 | $206 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
952 | $52 | $196 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
213 | $77 | $246 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
178 | $78 | $250 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
166 | $149 | $446 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
133 | $166 | $495 |
| COVID-19 amplified DNA/RNA probe detection A laboratory test that uses amplified DNA or RNA probes to detect the presence of severe acute respiratory syndrome coronavirus 2 (COVID-19) antigen. |
89 | $50 | $130 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
76 | $30 | $120 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
68 | $27 | $70 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
60 | $106 | $363 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
59 | $74 | $202 |
| Smoking cessation counseling, 4-10 minutes A brief counseling session focused on helping patients quit smoking and tobacco use. The provider spends 4 to 10 minutes discussing strategies and support for cessation. |
59 | $18 | $60 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
52 | $15 | $65 |
| New patient office visit, complex (60-74 min) | 50 | $203 | $580 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
39 | $108 | $280 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
21 | $201 | $581 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
19 | $153 | $517 |
| Transitional care management, high complexity Coordination of care for a patient transitioning from a short-term hospital stay or other facility to home or another care setting. This service addresses a high-complexity medical problem. |
16 | $245 | $715 |
| Smoking cessation counseling, more than 10 minutes Intensive counseling session focused on helping patients quit smoking and tobacco use, lasting more than 10 minutes. |
12 | $33 | $76 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$673,909
Total received (2018-2024)
Avg $96,273/year across 7 years
Top 0% in NY for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
45
Companies
1,347
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$666,589 (98.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,320 (1.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$103,582
2023
$182,160
2022
$113,586
2021
$48,394
2020
$39,304
2019
$118,322
2018
$68,560
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$94,915
GlaxoSmithKline, LLC.
$5,336
Grifols USA, LLC
$2,037
Boehringer Ingelheim Pharmaceuticals, Inc.
$260
Mylan Specialty L.P.
$193
Insmed, Inc.
$184
GENZYME CORPORATION
$114
ANI Pharmaceuticals, Inc.
$96
Electromed, Inc.
$81
Regeneron Healthcare Solutions, Inc.
$68
Vifor Pharma, Inc.
$66
HARMONY BIOSCIENCES LLC
$60
PFIZER INC.
$41
Takeda Pharmaceuticals U.S.A., Inc.
$34
Baxter Healthcare
$30
Actelion Pharmaceuticals US, Inc.
$30
Philips North America LLC
$23
Merck Sharp & Dohme LLC
$16
Top 3 companies account for 98.8% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$314,862
GlaxoSmithKline, LLC.
$195,125
Grifols USA, LLC
$142,537
Boehringer Ingelheim Pharmaceuticals, Inc.
$14,518
Mylan Specialty L.P.
$906
Hill-Rom Company, Inc
$875
Grifols Shared Services North America, Inc.
$820
Electromed, Inc.
$481
GENZYME CORPORATION
$408
Insmed, Inc.
$375
Regeneron Healthcare Solutions, Inc.
$316
Advanced Respiratory, Inc
$284
Sunovion Pharmaceuticals Inc.
$272
Philips Electronics North America Corporation
$248
ANI Pharmaceuticals, Inc.
$198
Baxter Healthcare
$173
Genentech USA, Inc.
$164
Fisher & Paykel Healthcare Inc
$149
Allergan, Inc.
$125
Novartis Pharmaceuticals Corporation
$117
PFIZER INC.
$115
Actelion Pharmaceuticals US, Inc.
$93
Amgen Inc.
$92
Merck Sharp & Dohme Corporation
$80
Vifor Pharma, Inc.
$66
HARMONY BIOSCIENCES LLC
$60
Nabriva Therapeutics, plc
$55
ADVANCED RESPIRATORY, INC
$35
Takeda Pharmaceuticals U.S.A., Inc.
$34
Merck Sharp & Dohme LLC
$30
CSL Behring
$27
Axsome Therapeutics, Inc.
$27
Boston Scientific Corporation
$25
Allergan Inc.
$24
Inogen, Inc.
$23
Philips North America LLC
$23
Harmony Biosciences LLC
$21
OptiNose US, Inc.
$19
JAZZ PHARMACEUTICALS INC.
$18
Exeltis, USA Inc.
$17
Olympus America Inc.
$16
Teva Pharmaceuticals USA, Inc.
$16
Janssen Pharmaceuticals, Inc
$14
AbbVie Inc.
$13
Shire North American Group Inc
$13
Top 3 companies account for 96.8% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (AK6) Vest Therapy · AIRSUPRA · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · AirDuo Digihaler · Arikayce · BOTOX · BREO · BREZTRI · BREZTRI AEROSPHERE · BROVANA · DIFICID · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · Dymista · EUCRISA · EXALT Model D · Esbriet · FARXIGA · FASENRA · GLASSIA · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · Hillrom - VisiVest Airway Clearance System · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · KEYTRUDA · LONHALA MAGNAIR · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · OPSUMIT MACITENTAN · Obstructive Sleep Apnea Device or Hospital Respiratory Equipment · Olympus Respiratory Devices · PT100US/myAIRVO 2 · PURIFIED CORTROPHIN GEL · Prolastin-C · Prolastin-C Liquid · Respiratoriy Care Undiv · SEEBRI · SEEBRI NEOHALER · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO · STIOLTO RESPIMAT · SYMBICORT · Sunosi · TEZSPIRE · TRELEGY ELLIPTA · The Vest System 205 Acute Care · The Vest System Model 105 Home Care · The VisiVest Airway Clearance System · Trilogy 100 · UPTRAVI · UTIBRON NEOHALER · Utibron · WAKIX · Wakix · Wellcentive Undiv · XARELTO · XOLAIR · XYWAV · Xenleta · Xhance · Xolair · YUPELRI · Yupelri · ZERBAXA · Zemaira · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (99%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for pulmonary disease in NY.
Geographic Context
Pulmonary diseases within 10 mi
75
Per 100K population
4.9
County median income
$128,329
Nearest hospital
JOHN T MATHER MEMORIAL HOSPITAL OF PORT JEFFERSON
3.1 mi
3.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Harris is a clinical cardiology specialist, with above-average Medicare volume (top 4% in NY), with speaking/promotional industry engagement in the top 0% of NY peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Harris experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Harris performed 1,867 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Harris receive payments from pharmaceutical companies?
Yes. Dr. Harris received a total of $673,909 from 45 companies across 1,347 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Harris's costs compare to other pulmonary diseases in Port Jefferson Station?
Dr. Harris's average Medicare payment per service is $69. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Harris) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Port Jefferson Station
Browse pulmonary diseases in Port Jefferson Station ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in NY
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in NY
Which NY pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Grifols USA, LLC Payments to Doctors
See all physicians who received payments from Grifols USA, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology